Understanding the Mechanism of Indomethacin-Saccharin Co-crystal Formation Using In-line Monitoring System based on PVM and FBRM
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Paul | - |
dc.contributor.author | Cho, Min-Yong | - |
dc.contributor.author | Choi, Guang J. | - |
dc.date.accessioned | 2021-08-11T15:24:00Z | - |
dc.date.available | 2021-08-11T15:24:00Z | - |
dc.date.issued | 2017-04 | - |
dc.identifier.issn | 0304-128X | - |
dc.identifier.issn | 2233-9558 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/7662 | - |
dc.description.abstract | Pharmaceutical co-crystals primarily to improve the solubility as well as stability of insoluble drug are to be investigated more intensively for IMDs as US FDA has reclassified co-crystal as a special case of solvates in August this year. In this study, we proposed a mechanism of indomethacin-saccharin co-crystal formation and the creation of transient indomethacin meta-stable form using in-line monitoring tools with the addition rate of anti-solvent as a critical process parameter. Among various instruments, we combined PVM (particle vision measurement) and FBRM (focused beam reflectance measurement) for the in-line monitoring of anti-solvent co-crystallization process. The off-line characterization of resulting powders was carried out employing the PXRD (powder x-ray diffraction) and DSC (differential scanning calorimeter). It was observed that the pathway to the final IMC-SAC co-crystal was significantly dependent upon the anti-solvent addition rate. The process conditions to obtain high quality co-crystal powder effectively were established. Consequently, we concluded that in-line monitoring combing the PVM and FBRM should be useful for the in-line monitoring of pharmaceutical co-crystallization processes. | - |
dc.format.extent | 10 | - |
dc.language | 한국어 | - |
dc.language.iso | KOR | - |
dc.publisher | 한국화학공학회 | - |
dc.title | Understanding the Mechanism of Indomethacin-Saccharin Co-crystal Formation Using In-line Monitoring System based on PVM and FBRM | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.9713/kcer.2017.55.2.180 | - |
dc.identifier.wosid | 000424599300005 | - |
dc.identifier.bibliographicCitation | Korean Chemical Engineering Research(HWAHAK KONGHAK), v.55, no.2, pp 180 - 189 | - |
dc.citation.title | Korean Chemical Engineering Research(HWAHAK KONGHAK) | - |
dc.citation.volume | 55 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 180 | - |
dc.citation.endPage | 189 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002207797 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | esci | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Engineering | - |
dc.relation.journalWebOfScienceCategory | Engineering, Chemical | - |
dc.subject.keywordPlus | AMORPHOUS INDOMETHACIN | - |
dc.subject.keywordPlus | DISSOLUTION RATE | - |
dc.subject.keywordPlus | SOLID FORMS | - |
dc.subject.keywordPlus | CRYSTALLIZATION | - |
dc.subject.keywordPlus | BEHAVIOR | - |
dc.subject.keywordPlus | STATE | - |
dc.subject.keywordPlus | COCRYSTALLIZATION | - |
dc.subject.keywordPlus | POLYMORPHS | - |
dc.subject.keywordPlus | CARBAMAZEPINE | - |
dc.subject.keywordPlus | FORMULATIONS | - |
dc.subject.keywordAuthor | Indomethacin (IMC) | - |
dc.subject.keywordAuthor | Saccharin (SAC) Co-crystallization | - |
dc.subject.keywordAuthor | Anti-solvent | - |
dc.subject.keywordAuthor | In-line monitoring | - |
dc.subject.keywordAuthor | FBRM | - |
dc.subject.keywordAuthor | PVM | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.